[Pharmacoeconomic model of the use of rifabutin in new cases of pulmonary tuberculosis].
The formalized procedures to commensurate the results and expenditures were used to make a comprehensive evaluation of the clinical efficiency and economical expediency of purposeful application of rifabutin in new cases of disseminated and destructive pulmonary tuberculosis.